The tests will be available for HCA patients who meet screening criteria, according to an Oct. 17 press release. HCA’s affiliate, the Nashville-based Sarah Cannon Cancer Institute, will lead the Grail test partnership.
The Galleri test is the first clinically validated test that can detect shared cancer signals across more than 50 types of cancer using a blood draw.
HCA is also participating in an interventional study of the Galleri test in Nashville, Denver, Austin, Texas, and Asheville, N.C.
